| Code | Description | Claims | Beneficiaries | Total Paid |
|---|
| 88305 |
Level IV - Surgical pathology, gross and microscopic examination |
11,283 |
10,074 |
$664K |
| U0004 |
2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc, making use of high throughput technologies as described by cms-2020-01-r |
5,815 |
5,427 |
$553K |
| 88307 |
|
2,908 |
2,648 |
$276K |
| 87491 |
Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe |
2,473 |
2,253 |
$94K |
| 87591 |
Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe |
2,477 |
2,255 |
$94K |
| 87624 |
Infectious agent detection by nucleic acid; human papillomavirus (HPV), high-risk types |
2,916 |
2,686 |
$92K |
| 88304 |
|
2,855 |
2,533 |
$77K |
| 88175 |
Cytopathology, cervical or vaginal, any reporting system; collected in preservative fluid, automated thin layer |
5,042 |
4,720 |
$74K |
| U0002 |
2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc |
625 |
489 |
$24K |
| 88342 |
|
466 |
393 |
$18K |
| 87661 |
Infectious agent detection by nucleic acid; Trichomonas vaginalis, amplified probe |
403 |
348 |
$14K |
| 88142 |
|
1,346 |
1,123 |
$14K |
| 88341 |
|
104 |
82 |
$12K |
| 88302 |
|
14 |
13 |
$691.86 |
| 88141 |
|
211 |
183 |
$629.14 |
| U0005 |
Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 |
3,976 |
3,642 |
$475.00 |
| 87635 |
Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe |
192 |
95 |
$21.55 |